Exercise Prehabilitation Among Older Patients With Hematological Malignancies Preparing For CAR-T Cell Immunotherapy

Sponsor
H. Lee Moffitt Cancer Center and Research Institute (Other)
Overall Status
Recruiting
CT.gov ID
NCT05763563
Collaborator
Cancer and Aging Research Group (Other)
20
1
1
16.2
1.2

Study Details

Study Description

Brief Summary

The purpose of the study is to evaluate an exercise program for individuals preparing for Chimeric Antigen Receptor (CAR) T-cell immunotherapy for hematological malignancies.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Resistance Training
  • Behavioral: Aerobic Exercise
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Feasibility Of Exercise Prehabilitation Among Older Patients With Hematological Malignancies Preparing For Chimeric Antigen Receptor (CAR) T-Cell Immunotherapy
Actual Study Start Date :
Feb 23, 2023
Anticipated Primary Completion Date :
Jul 1, 2024
Anticipated Study Completion Date :
Jul 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Exercise prehabilitation

Participants will take part in an exercise program in which they will be encouraged to perform approximately 30 minutes of resistance training exercises approximately twice per week until they undergo CAR-T therapy (Approximately 4-6 weeks). Participants will also be encouraged to perform moderate aerobic exercise such as brisk walking or using stationary aerobic equipment at least 3 times per week. Participants will wear a FitBit fitness watch to monitor aerobic exercise.

Behavioral: Resistance Training
Participants will be encouraged to perform approximately 30 minutes of resistance training exercises twice per week, until they undergo CART-T therapy. Exercises will be performed using resistance tubes (Bodylastics Resistance Bands Set) and a connectable bar (Bionic Body Workout Bar) that mimics a weighted barbell when tubes are attached. The tubes provide up to 142 pounds of resistance (adjustable in increments between 3-10 pounds) when simultaneously connected to handles or bar, and multiple tubes can be attached simultaneously.

Behavioral: Aerobic Exercise
Participants will be encouraged to perform ≥30 minutes of moderate-intensity aerobic exercise on ≥3 days per week. Aerobic exercise intensity will be guided by heart rate zones, with participants exercising at 50-70% of their age-predicted maximum heart rate in bouts of at least 10 minutes at a time. Participants will be encouraged to gradually increase exercise intensity and duration until they are meeting the recommendation

Outcome Measures

Primary Outcome Measures

  1. Percentage of Participants that Enroll and Consent - Enrollment Feasibility [Up to 12 Months]

    Enrollment will be considered feasible if ≥60% of eligible and approached patients actually consent and enroll

  2. Percentage of Participants that Complete Study Assessments - Retention Feasibility [Up to 3 Months]

    Retention will be considered feasible if ≥70% of participants complete study measures

  3. Adherence - Feasibility [Up to 3 Months]

    Adherence will be based on participants attending ≥ 70% of tele-RT sessions on average and performing ≥ 70% of prescribed moderate-intensity aerobic exercise per week

  4. Participant Evaluation of Feasibility and Acceptability - Acceptability [Up to 3 Months]

    Participants evaluation of feasibility and acceptability will be assessed with a questionnaire, adapted to fit the intervention. The questionnaire includes both Likert Scale and open-ended questions. An item-by-item basis and as average item score, with scores ≥4 ("agree" to "strongly agree") indicating acceptability. Open-ended responses will be analyzed qualitatively to inform intervention improvement.

  5. Participant Self-Reported Musculoskeletal Injuries - Safety [Up to 3 Months]

    The numerator of the safety variable will be the number of musculoskeletal injuries or adverse health events reported as "likely related" or "definitely related" the exercise programming and that caused at least some limitation of daily activity lasting more than 3 days. The denominator of the safety variable will be the number of exercise sessions performed by the participant (tele-resistance training plus aerobic exercise sessions lasting ≥10 minutes). The intervention will be considered safe if the rate of musculoskeletal injuries (i.e., muscle strains or pulls, sprains, exacerbated bone pain, fractures or breaks, or other adverse health events incurred during exercise sessions) is lower than the published metric of 11.9 injuries per 1000 sessions, as used as a benchmark in previous exercise oncology research

  6. Objective physical functioning and fitness - Baseline [At Baseline]

    Physical functioning and fitness will be assessed using the 30-second chair stand test,30-second arm curl test, and treadmill 6-minute walk test.

  7. Objective physical functioning and fitness - Follow-up [Up to 3 Months]

    Physical functioning and fitness will be assessed using the 30-second chair stand test,30-second arm curl test, and treadmill 6-minute walk test.

  8. Participant Skeletal Muscle Index (SMI) - Baseline [Baseline]

    Participants SMI will be measured using Tomovision SliceOMatic software and clinical, computerized tomography (CT) scans

  9. Participant Skeletal Muscle Index (SMI) - Follow-up [After CAR-T Therapy, Up to 6 Months]

    Participants SMI will be measured using Tomovision SliceOMatic software and clinical, computerized tomography (CT) scans

  10. Participants Health-Related Quality of Life - Baseline [Baseline]

    Participants health-related quality of life will be measured using the 12-item Medical Outcomes Study Short Form Survey

  11. Participants Health-Related Quality of Life - At 3 Months [Up to 3 Months]

    Participants health-related quality of life will be measured using the 12-item Medical Outcomes Study Short Form Survey

  12. Participants Health-Related Quality of Life - At 6 Months [Up to 6 Months]

    Participants health-related quality of life will be measured using the 12-item Medical Outcomes Study Short Form Survey

  13. Participant Self Reported Exercise - Baseline [Baseline]

    Participant self-reported exercise will be measured using a modified Godin Leisure Time Exercise Questionnaire to assess both aerobic and resistance exercise

  14. Participant Self Reported Exercise - At 3 Months [Up to 3 Months]

    Participant self-reported exercise will be measured using a modified Godin Leisure Time Exercise Questionnaire to assess both aerobic and resistance exercise

  15. Participant Self Reported Exercise - At 6 Months [Up to 6 Months]

    Participant self-reported exercise will be measured using a modified Godin Leisure Time Exercise Questionnaire to assess both aerobic and resistance exercise

Eligibility Criteria

Criteria

Ages Eligible for Study:
65 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age ≥65 years

  • Lymphoma, leukemia, or myeloma with commercial FDA-approved CAR-T delivery planned for ≥4 weeks following enrollment

  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2

  • Able to read and speak English fluently

  • Capable of providing informed consent

Exclusion Criteria:
  • Regular engagement in Resistance training (2x/week targeting all major muscle groups)

  • Screen failure for exercise safety based on Physical Activity Readiness Questionnaire (PAR-Q) and Patient-Reported Measurement Information System (PROMIS) screening questions

  • Underlying unstable cardiac or pulmonary disease or symptomatic cardiac disease (New York Heart Association functional class III or IV).

  • Recent fracture or acute musculoskeletal injury that precludes ability to participate in RT using body weight

  • Numeric pain rating scale of ≥ 7 out of 10

  • Myopathic or rheumatologic disease that impacts physical function

  • Cognitive, visual, or auditory limitations that preclude safe engagement in remotely-supervised resistance training sessions or independent aerobic exercise (as determined by patients' treating oncologists and specified in clinic notes outlining disease history).

Contacts and Locations

Locations

Site City State Country Postal Code
1 Moffitt Cancer Center Tampa Florida United States 33612

Sponsors and Collaborators

  • H. Lee Moffitt Cancer Center and Research Institute
  • Cancer and Aging Research Group

Investigators

  • Principal Investigator: Nathan Parker, PhD, MPH, Moffitt Cancer Center
  • Principal Investigator: Ciara Freeman, MD, PhD, Moffitt Cancer Center

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
H. Lee Moffitt Cancer Center and Research Institute
ClinicalTrials.gov Identifier:
NCT05763563
Other Study ID Numbers:
  • MCC-22115
First Posted:
Mar 10, 2023
Last Update Posted:
Mar 10, 2023
Last Verified:
Feb 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 10, 2023